In a nutshell This study evaluated the long-term effectiveness and safety of a new chemotherapy regimen in patients with previously untreated indolent (painless) non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen is effective and well-tolerated for these patients. Some background There are three common types of painless NHL....
Read MoreCurrent disease status-First occurrence of the lymphoma Posts on Medivizor
Is nivolumab an effective treatment for relapsed and unresponsive Hodgkin lymphoma?
In a nutshell This study examined if nivolumab is an effective treatment for relapsed and unresponsive Hodgkin lymphoma. This study concluded that nivolumab is an effective treatment for these patients, regardless of previous stem cell treatment status. Some background Standard treatment for patients with Hodgkin lymphoma (HL) which has relapsed or...
Read MoreEvaluating the impact of interim imaging on treatment outcomes for advanced cHL
In a nutshell This study investigated the impact of interim functional imaging (IFI) on the outcomes of treatment for advanced classical Hodgkin lymphoma (cHL). This study found that patients with positive scan results were more likely to disease progression. Some background ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is the...
Read MoreIs active surveillance effective in managing NLPHL?
In a nutshell This study evaluated the outcomes of active surveillance versus upfront treatment for patients with nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL). It was found that active surveillance is effective for managing NLPHL. Some background NLPHL is a rare subtype of non-Hodgkin's lymphoma. It may be treated with intensive...
Read MorePredicting outcomes using the MIPI score for newly-diagnosed patients with MCL
In a nutshell This study evaluated the use of the MIPI score for patients with newly diagnosed mantle cell lymphoma (MCL). This study concluded that the MIPI score may better predict prognosis for these patients. Some background MCL is a type of non-Hodgkin’s lymphoma that significantly differs between individual patients. The MCL international...
Read MoreCombining ibrutinib and umbralisib to treat relapsed/unresponsive mantle cell lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive mantle cell lymphoma (MCL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in these patients. Some background Mantle cell...
Read MoreEvaluating A+AVD for patients with newly diagnosed advanced Hodgkin lymphoma
In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) plus chemotherapy for patients with advanced (stage 3 – 4) Hodgkin’s lymphoma (HL). This study concluded that this treatment is effective for these patients. Some background The most commonly used frontline chemotherapy regimen for advanced HL...
Read MoreIs BRESHAP an effective treatment for relapsed and unresponsive Hodgkin lymphoma?
In a nutshell This study examined how safe and effective brentuximab vedotin (Adcedris) is when added to conventional treatments for relapsed and unresponsive Hodgkin lymphoma. This study concluded that this treatment is safe and effective when used as part of the treatment for Hodgkin lymphoma. Some background Standard treatment for...
Read MoreReviewing treatment strategies for early-stage Hodgkin lymphoma
In a nutshell This article reviews treatment strategies for patients with early-stage (stage 1 – 2) Hodgkin lymphoma (HL). Some background One of the main treatment goals for patients with HL is to improve long-term outcomes. However, many patients experience complications decades after initial treatment. These may include secondary cancer...
Read MoreSintilimab in relapsed or unresponsive Hodgkin lymphoma
In a nutshell This study examined the safety and effectiveness of sintilimab in patients with relapsed or unresponsive Hodgkin lymphoma. This study concluded that sintilimab could be a new treatment option for these patients. Some background Hodgkin disease (HD) is a type of lymphoma. In patients who relapse or do not respond to first-line...
Read MoreLong-term outcomes of radioimmunotherapy for patients with follicular lymphoma
In a nutshell This study evaluated the long-term outcomes of radioimmunotherapy (RIT) in patients with follicular lymphoma (FL). This study concluded that RIT is a safe and effective long-term treatment option for these patients. Some background FL is the most common type of non-Hodgkin’s lymphoma. The current standard first-line treatment for...
Read MoreEvaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma
In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...
Read More
